This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
for Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Drug: Mevrometostat
120 locations incl. Huntsville
Sponsor: Pfizer
Sex: Male·Age: 18+
Code: NCT07028853·Phase 3·Recruiting